In a child with cardiogenic shock, which agent—epinephrine (adrenaline), dobutamine, or milrinone—is preferred based on the patient's hemodynamic profile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Epinephrine for Severe Shock, Dobutamine for Moderate Dysfunction, Milrinone for High Afterload

In pediatric cardiogenic shock, epinephrine is preferred for marked circulatory instability and decompensated shock, dobutamine for moderate myocardial dysfunction with preserved blood pressure, and milrinone for myocardial dysfunction with elevated systemic or pulmonary vascular resistance. The choice depends critically on the hemodynamic profile: blood pressure, cardiac output, and vascular resistance 1.

Hemodynamic-Based Selection Algorithm

Severe Shock with Marked Instability (Low BP, Low Cardiac Output)

  • Epinephrine (0.1-1 mcg/kg/min) is the first-line agent 1
  • The 2010 AHA PALS guidelines explicitly state: "Epinephrine or norepinephrine may be preferable to dopamine in patients (especially infants) with marked circulatory instability and decompensated shock" 1
  • Low doses (<0.3 mcg/kg/min) provide β-adrenergic effects (potent inotropy with some vasodilation)
  • Higher doses (>0.3 mcg/kg/min) add α-adrenergic vasoconstriction to support blood pressure 1
  • This is particularly important in infants, where epinephrine's combined inotropic and vasopressor effects are critical for survival

Moderate Dysfunction with Preserved Blood Pressure (BP >100 mmHg, Low Cardiac Output)

  • Dobutamine (2-20 mcg/kg/min) is the preferred agent 1, 2
  • Increases myocardial contractility through β1- and β2-adrenergic receptor stimulation 1
  • Decreases peripheral vascular resistance, improving cardiac output without excessive vasoconstriction 2
  • The 2010 guidelines state: "Dobutamine increases myocardial contractility and can decrease peripheral vascular resistance. Titrate the infusion to improve cardiac output and blood pressure due to poor myocardial function" 1
  • FDA labeling confirms effectiveness in pediatric patients at all ages, with dose titration essential due to wide individual variability 2

High Afterload States (Elevated SVR or PVR, Normal or Low BP)

  • Milrinone (loading 50 mcg/kg over 10-60 min, then 0.25-0.75 mcg/kg/min) is the optimal choice 1
  • The 2010 AHA guidelines recommend: "It is reasonable to use an inodilator in a highly monitored setting for treatment of myocardial dysfunction with increased systemic or pulmonary vascular resistance" 1
  • Provides inotropy with vasodilation (both systemic and pulmonary) while minimally increasing myocardial oxygen demand 1
  • The 2010 International Consensus confirms milrinone is "effective in preventing low cardiac output syndrome in infants and children following biventricular cardiac repair" 3, 4
  • Critical caveat: Long half-life means delayed steady-state effects and slowly reversible hypotension 1
  • Fluid administration may be required due to vasodilatory effects 1

Evidence Quality and Nuances

The 2010 AHA PALS guidelines acknowledge: "There are no studies evaluating the benefit of specific vasoactive agents after ROSC in infants and children" 1. However, the 2010 International Consensus on cardiogenic shock provides stronger evidence 3, 4:

  • Dopamine vs. Dobutamine: Six LOE 3 studies showed both improve hemodynamics, but dopamine at >7 mcg/kg/min increases pulmonary vascular resistance—problematic in cardiogenic shock 3, 4
  • Milrinone superiority: One LOE 1 pediatric RCT showed milrinone provided better hemodynamics and shorter ICU stays compared to low-dose epinephrine plus nitroglycerin after tetralogy of Fallot repair 3, 4
  • Recent observational data: A 2023 study of 250 infants undergoing complex cardiac surgery found milrinone-epinephrine combinations associated with higher morbidity/mortality than dobutamine alone (27.4% vs 13.9%, P=0.016), though this may reflect selection bias toward sicker patients 5

Critical Pitfalls to Avoid

  1. Don't use dopamine as first-line in severe shock: The guidelines explicitly favor epinephrine over dopamine in marked instability, especially in infants 1

  2. Avoid milrinone loading in hypotensive patients: The vasodilatory effects can worsen hypotension; use cautiously and ensure adequate preload 1, 6

  3. Don't ignore the hemodynamic profile: All three agents can worsen outcomes if mismatched to physiology. A child with high SVR given epinephrine will have worsening afterload; a hypotensive child given milrinone may decompensate 7

  4. Monitor for catecholamine toxicity: All agents can cause tachyarrhythmias, hypertension, hyperglycemia, increased lactate, and hypokalemia 1

  5. Titrate aggressively: The 2010 guidelines emphasize "great interpatient variability in response" requiring individualized dosing 1

Practical Implementation

The 2013 Canadian Cardiovascular Society guidelines provide additional context: "Inotropic therapy should be confined to patients with depressed systolic function and clinical evidence of low cardiac output syndrome who can be closely monitored" 6. They recommend milrinone, dobutamine, and low-dose epinephrine as having "all shown efficacy in children" with cardiogenic shock 6.

For resource-limited settings, the 2012 recommendations suggest dopamine or epinephrine for persistent tissue hypoperfusion despite fluid resuscitation, with preference for norepinephrine when available due to less lactic acidosis 8.

The 2009 ACCM septic shock guidelines provide the most detailed hemodynamic algorithm, stratifying by cardiac index and SVR, which applies equally to cardiogenic shock 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.